NMPA CDE issues guidance on common formats for manufacturing processes and quality standards of Chinese medicines, chemicals and biological products
On July 19, 2021, the Center for Drug Evaluation of the NMPA released the "Common Formats and Writing Guidelines for Manufacturing Processes and Quality Standards of Chinese Medicines, Chemical Drugs and Biological Products". The notice of the guideline is as follows; the attachment documents of the guideline can be downloaded from the official CDE website (www.cde.org.cn).
In accordance with the Measures for the Administration of Drug Registration (Order No. 27 of the State Administration for Market Regulation), and to standardize the submission of application materials, under the deployment of the NMPA, the CDE organized the formulation of the "Common Formats and Writing Guidelines for Manufacturing Processes and Quality Standards of Chinese Medicines, Chemical Drugs and Biological Products" (see Attachments 1-3). Upon review and approval by the NMPA, it is hereby released and takes effect from the date of release.
From the date of release of this document, for drug registration applications submitted by applicants that involve the approval of manufacturing processes and quality standards, the manufacturing processes and quality standards shall be written in accordance with the common formats in the attachments. For varieties under review involving the approval of manufacturing processes and quality standards, where the applicant has not yet contacted or is in contact with the Center, approval shall follow the common formats in the attachments; where contact has been completed, review and approval may continue under the original common formats.
It is hereby notified.
Attachments: 1. Common formats and writing guidelines for manufacturing processes and quality standards of Chinese medicines; 2. Common formats and writing guidelines for manufacturing processes and quality standards of chemical drugs; 3. Common formats and writing guidelines for manufacturing processes and quality standards of biological products.
Center for Drug Evaluation, NMPA. July 15, 2021.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.